Quantcast
Channel: Europe Headlines on One News Page [United Kingdom]
Viewing all 65275 articles
Browse latest View live

5 Top Picks: The World’s Best-Value Beach Towns—Internationalliving.com

$
0
0
Retirees don’t need deep pockets to retire on the beach, according to a new report from the editors of InternationalLiving.com. In the world’s best-value coastal escapes, a budget of as little as $2,000 a month can fund a couple’s comfortable retirement in the sun, complete with sailing, surfing, fishing, diving, and cocktails on the sand.

BALTIMORE (PRWEB) February 28, 2018

“Most folks put a retirement at the beach in the realm of fantasy. Having a place on the ocean, soaking in the sun, spending laidback days with toes in the sand, fishing, diving, sailing, surfing, walking on the beach at dusk with a cocktail in hand...that’s a ‘rich man’s retirement,’ in most people’s assessment,” says IL Executive Editor Jennifer Stevens.

“But in the right places around the world, in fact, Baby Boomers can retire on the coast and live really well, while spending less than it would cost them to stay home.”

A new report from the editors of International Living points to a series of beach-town gems in Latin America, Europe, and Southeast Asia where retirees can “live large” on a modest budget.

These towns are all located within countries that appear on International Living’s Annual Global Retirement Index 2018—Costa Rica, Panama, Ecuador, Malaysia, and Portugal among them—which offer safe, welcoming, and picturesque beach towns in which expat retirees report that they are enjoying fun, healthy, fulfilling lifestyles on a modest budget.

In the countries compared and contrasted in IL’s Annual Global Retirement Index 2018, readers will find many good-value beaches, the editors report. Here are five international picks worthy of note:

Tamarindo, Costa Rica

There’s a saying in Costa Rica: Pura Vida. It basically means “Life is Good.” People are content and happy. It’s an attitude and a way of life. And this year, for the first time, Costa Rica takes the top spot in InternationalLiving.com’s 2018 Global Retirement Index.

The Pacific-coast beach town of Tamarindo is a place of natural abundance, offering fresh produce and seafood, clean air, and more than two miles of golden sand.

Tamarindo is situated within one of the world’s “Blue Zones”—areas where people regularly reach the age of 100 in good health. And, expats report, it’s a surf town that values fitness and embraces an outdoorsy culture.

“It gave me the impression of a ’60s California beach town with surf shops and the waves,” says Bill Sherman of what drew him and his wife Pokey to the town. “We both felt very comfortable. There are no high-rises on the beach. You just see trees.”

The couple lives in a fifth-floor condo, on a hill that overlooks the beach town as well as the forest along the gold-sand beach and out over the deep blue of the Pacific.

“It’s a real joy to wake up and come out here and realize what we’ve done,” says Pokey.

Tamarindo is accessible for a couple on $2,500 a month (housing included), and in addition, Costa Rica offers high-quality but low-cost medical care, good-value real estate, established expat communities, and welcoming locals.

Pedasi, Panama

Pedasí, a four-hour trip from Panama City, sits on the tip of the Azuero Peninsula, providing a relaxed setting for expats like Jim Gault and his wife, Abbe.

“Our lives here are a far cry from the hectic existence we lived back in Florida,” says Jim.

“Our retirement is a constant buzz of activity, but only because we want it to be. We prefer early mornings with a beautiful sunrise, cool clean breezes, and a low tide to reveal some of the rugged, multi-colored rock formations. Often, we have the beach all to ourselves. During our walk, we plan horseback rides, day trips, playing bingo or cards, or dinner with friends at a nice restaurant.”

This is the life they have created for themselves in the small town on Panama’s Pacific coast. Unspoiled, dark brown beaches are coupled with often stunning rock formations and warm Pacific waters. Large cattle ranches and corn fields surround the village.

“In many ways, it reminds me of small-town America 50 years ago. Everyone here is so friendly. Walking home in the dark after a nice meal often means walking by a group of teenagers. On a dark street in a U.S. city, that might be scary. Not so in Pedasí. The teens just greet you with buenas noches (good evening).

“We were drawn to Pedasí for its proximity to the ocean; small-town feel; clean, fresh air; the friendliness of its 1,500 inhabitants; and the well-established expat community.”

The cost of living in Pedasí is another big plus. The Gaults own their own home and vehicle and Jim says, “I’m collecting my Social Security and we live comfortably on $2,000 a month, including several trips within Panama and one trip abroad per year.

“A beer is $1 to $2 a bottle, our car insurance is just $600 for the year, and we have a housekeeper for just $15 for a half day. I have two different gardeners and several handymen who help me with our home for $5 an hour.”

Salinas, Ecuador

“When my wife Rita and I moved to Ecuador, all we were really looking for was a nice climate,” says IL Coastal Ecuador Correspondent, Jim Santos. “After years of shivering through snowy Maryland winters, followed by hot and humid summers, we wanted to live somewhere that is comfortable year-round.”

They found this on Ecuador’s Pacific coast, in Salinas. The beach is wide, sandy, and clean, bordered by the blue, calm waters. Located at Ecuador’s western-most point, Salinas is sometimes called “Little Miami Beach.”

Daily costs in Salinas are low. Retirees who move to the relatively small Ecuadorian town, see a huge plummet in expenses with couples living a comfortably on $1,405 per month.

“We knew that we would spend less money, as well,” says Jim. “We traded property taxes of $5,000 a year for a tax bill of $279. Our condo maintenance fees in Maryland were $1,000 a month; in Salinas, just $197.

“But we didn’t expect that living overseas would improve our health.”

Only two degrees south of the equator, Salinas is a great place for those who want to escape the long, cold North American and Canadian winters. The sunny season goes from mid-December through April. The warmest waters are between January and March making it a perfect beach destination for an active lifestyle.

When the Santos’ first started to think about moving overseas in 2012, Jim was morbidly obese, weighing 319 pounds at one stage. He took two different medications a day for Type II diabetes, and one for high blood pressure.

“Moving to Ecuador changed everything. After a few months, I’d lost 25 pounds. By the end of the first year, I was down another 10 pounds, and I had to reduce the dosages on my diabetes medications to prevents sugar lows.

“All of this has come about without a fad diet or rigorous exercise plan, without daily visits to the gym—although there is a very nice one in our condo building—but simply through enjoying the healthier lifestyle we naturally have here on the beach.”

Penang, Malaysia

One of the oldest outposts of the former British Empire, Penang delivers 110 square miles of tropical treasures. It offers a perfect balance of nature and sophisticated amenities that make it a wonderful haven for expats. It boasts lush jungle-covered hills bursting with wildlife, as well as fancy modern high-rises and pristine beaches.

Attracted by the relaxed lifestyle and enticing low living costs, retirees from across the globe have settled here. And almost everyone speaks English, so communicating is easy.

In 2010, Larry John from British Columbia, Canada, paid $142,000 for his three-bedroom, two-bathroom condo with a sea view in Penang. It’s off a tree-lined street in a well-kept, gated development, with a top-of-the-line gym and swimming pool.

“In Canada, to find something similar to what I have now, with an Olympic-size swimming pool, wading pool, Jacuzzi pool, tennis court (which can be used year-round), gym, games room, and conference and meeting rooms, would cost at least 50% more, with much higher condo fees and property taxes,” he says.

“The cost of living is low, and the multitude of shopping malls and restaurants makes Penang a great place to retire,” says Larry. “But the 10-year MM2H visa is probably the biggest benefit that Malaysia offers.”

Larry’s budget—and he’s living well on it—is less than $1,600 a month, now that he owns his own home. “It’s great for those on a fixed income or self-financing their retirement,” he says.

Cascais, Portugal

Rated the third-safest country in the world in the 2017 Global Peace Index, Portugal is not only secure, but beautiful.

Cascais is a beach haven about 20 minutes from the capital, Lisbon. With its boutique-lined streets and many art vendors and vintage carousels, this town is like something out of a storybook. Yet its sunny shores, friendly inhabitants, and modest prices are no fantasy.

In summer, the average daytime high here is 73 degrees with low of 63. And in the winter, it’s almost always about 50 degrees. You can golf nearby, and favorable wind conditions make the stretch of coast along here ideal for sailing, surfing, kite-surfing, and windsurfing, too. Plus English is widely spoken.

Here you can rent a condo from about $750 month. A light-filled two-bedroom place with a sea view—fully renovated and furnished—right near all the conveniences you could need and a 10-minute walk to the train station rents for $1,114.

One of IL Portugal Correspondent Tricia Pimental’s favorite spots is Conceição, the beach closest to the town of Cascais. She says, “Its impressive former fortress, now a five-star hotel, overlooks a bay dotted with bobbing fishing boats. Visit once and you’ll see why it’s called ‘the Portuguese Riviera.’

“Living outdoors here is easy, thanks to the generous climate.”

Annette Ford Rio who lives in Cascais echoes these sentiments. She said, “The blue-green water is absolutely fantastic with the sun shining on the sea; it’s as if diamonds are dancing on it. The sunrise and sunsets are fabulous.”

This beach town is one of Europe’s best-kept secrets...and on $2,500 a month, a couple could live very comfortably here.
More details can be found here: Annual Global Retirement Index 2018

Editor's Note: Members of the media have permission to republish the article linked above once credit is given to InternationalLiving.com.

Further information, as well as interviews with expert authors for radio, TV or print, is available on request. Photos are also available.

For information about InternationalLiving.com content republishing, source material or to book an interview with one of our experts, contact PR Managing Editor, Marita Kelly, +001 667 312 3532, mkelly@internationalliving.com
Twitter: @inliving
Facebook: https://www.facebook.com/International.Living/

About International Living

For 37 years, InternationalLiving.com has been the leading authority for anyone looking for global retirement or relocation opportunities. Through its monthly magazine and related e-letters, extensive website, podcasts, online bookstore, and events held around the world, InternationalLiving.com provides information and services to help its readers live better, travel farther, have more fun, save more money, and find better business opportunities when they expand their world beyond their own shores. InternationalLiving.com has more than 200 correspondents traveling the globe, investigating the best opportunities for travel, retirement, real estate, and investment. Reported by PRWeb 51 minutes ago.

Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate Update

$
0
0
DUBLIN, Ireland and TREVOSE, Pa., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Monday, March 12 at 8:30 a.m. ET to discuss the Company’s fourth quarter and year-end 2017 financial results and provide a corporate update. The conference call will follow the anticipated release of the Company’s financial results earlier that day.*Event Details*
Strongbridge will host a conference call on Monday, March 12 at 8:30 a.m. ET. To access the live call, dial 844-285-7153 (domestic) or 478-219-0180 (international) with conference ID 6497969. The conference call will also be audio webcast from the Company’s website at www.strongbridgebio.com under the “Investor/Webcasts and Presentations” section. A replay of the call will be made available for one week following the conference call. To hear a replay of the call, dial 855-859-2056 (domestic) or 404-537-3406 (international) with conference ID 6497969.

*About Strongbridge Biopharma*
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis^® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.

*Contacts:*

*Corporate and Media Relations*
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com

*Investor Relations*
*United States:*
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com

*Europe:*
First House
Mitra Hagen Negård
+47 21 04 62 19
strongbridgebio@firsthouse.no

*USA*
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389 Reported by GlobeNewswire 36 minutes ago.

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

$
0
0
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is joining the global initiative to raise awareness of Rare Disease Day®, an international campaign led by the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD), dedicated to elevating the public understanding of rare diseases. Much like the similar global initiative in 2017, this year’s activities will focus attention on the importance of research and will highlight the roles both researchers and patients play in advancing research towards potential treatments for rare diseases.“Today we stand with EURORDIS and NORD to recognize Rare Disease Day and shine a light on the innovations that power research focused to novel therapies for people living with rare diseases,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In addition to ongoing Phase 2 clinical trials of reldesemtiv, our next-generation fast skeletal muscle activator directed to the potential treatment of ALS and SMA, we are also proud to be advancing three new potential drug candidates from our research that may address needs of patients with rare diseases.”

Cytokinetics is collaborating with Astellas to develop reldesemtiv, a next-generation fast skeletal troponin muscle activator (FSTA), which is the subject of four ongoing clinical trials, including Phase 2 clinical trials directed to the potential treatment of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Results from both these clinical trials are expected in 2018.

*About Rare Disease Day*

Rare Disease Day, which takes place every year on the last day in February, was established in Europe in 2008 by the European Organisation for Rare Diseases (EURORDIS), and is now observed in more than 80 nations. In the United States, Rare Disease Day is sponsored by the National Organization for Rare Disorders (NORD), a leading independent, non-profit organization committed to the identification, treatment, and cure of rare diseases. According to the National Institutes of Health (NIH), in the US, a rare disease is defined as one that affects fewer than 200,000 people. With over 6,000 rare diseases, 25 million Americans are living with a rare disease, but only 5 percent of these diseases have a treatment.

*About ALS*

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that afflicts approximately 30,000 people in the United States and a comparable number of patients in Europe. Approximately 6,000 new cases of ALS are diagnosed each year in the United States. The average life expectancy of an ALS patient is approximately three to five years after diagnosis and only 10 percent of patients survive for more than 10 years. Death is usually due to respiratory failure because of diminished strength in the skeletal muscles responsible for breathing. Few treatment options exist for these patients, resulting in a high unmet need for new therapies to address functional deficits and disease progression.

*About SMA*

SMA is a severe neuromuscular disease that occurs in 1 in every 6,000 to 10,000 live births each year and is one of the most common potentially fatal genetic disorders. Spinal muscular atrophy manifests in various degrees of severity as progressive muscle weakness resulting in respiratory and mobility impairment. There are four types of SMA, named for age of initial onset of muscle weakness and related symptoms: Type I (Infantile), Type II (Intermediate), Type III (Juvenile) and Type IV (Adult onset).  Life expectancy and disease severity vary by type of SMA. Type I patients have the worst prognosis, with a life expectancy of no more than 2 years; Type IV patients may have a normal life span but eventually suffer gradual weakness in the proximal muscles of the extremities, eventually resulting in mobility issues. Few treatment options exist for these patients, resulting in a high unmet need for new therapeutic options to address symptoms and modify disease progression.

*About Cytokinetics*

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (“Amgen”) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is collaborating with Astellas Pharma Inc. (“Astellas”) to develop reldesemtiv (CK-2127107), a next-generation FSTA. Reldesemtiv has been granted orphan drug designation by the FDA for the potential treatment of SMA. Reldesemtiv is the subject of three ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. Astellas is also conducting a Phase 1b clinical trial of reldesemtiv in elderly adults with limited mobility. Astellas holds an exclusive worldwide license to develop and commercialize reldesemtiv. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. Cytokinetics continues its 20-year history of innovation with three new muscle biology directed compounds advancing from research to development in 2018.  For additional information about Cytokinetics, visit www.cytokinetics.com.

*Forward-Looking Statements *

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities; the design, results, significance and utility of preclinical study results; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

*Contact:*
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757 Reported by GlobeNewswire 36 minutes ago.

Digital Writing Instruments Market Growing at a CAGR of 9.4% by 2027- Future Market Insights

$
0
0
VALLEY COTTAGE, NY, Feb. 28, 2018 (GLOBE NEWSWIRE) -- *Digital Writing Instruments Market: Snapshot*

E-learning is becoming the next generation education system. With the growth of e-learning and various advancements taking place in technology, the growth of digital writing instruments is inevitable. Future Market Insights outlines a complete scenario of the digital writing instruments market in its new report titled ‘Digital Writing Instruments Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027).’ The report covers the demand analysis for various products in the digital writing instruments market along with an analysis of different segments associated with the market. According to the key outcomes of this market research, the global digital writing instruments market is expected to witness an exponential growth in the coming years.

The global market is expected to reach a market value of over US$ 2,200 Mn by the end of 2027, growing at a CAGR of 9.4% during the forecast period. The growth is primarily driven by the preference of individuals towards advanced technologies and their dependency on it. The mobile and tablets market is also at its all-time high, which has in-turn influenced the demand for digital writing instruments in the global market. The manufacturers are expected to make full use of the current trends and come up with innovative writing instruments, in order to attract more buyers.

*Request a Sample Report with Table of Contents and Figures*: https://www.futuremarketinsights.com/reports/sample/rep-gb-5210

*Digital Writing Instruments Market: Segmental Analysis*

Based on *region*, North America dominates the market with its expected market value of over US$ 850 Mn by the end of 2027. However, in terms of growth rate, Western Europe has emerged as the leading region with 10.2% CAGR during the forecast period.

On the basis of *product type*, digital pens and pencils is expected to remain a dominating segment throughout the forecast period, leaving behind digital stylus. However, digital stylus segment is also expected to witness a relatively slow yet growing demand.

On the basis of device *compatibility*, tablets are the current leaders with a market size of over US$ 1,400 Mn by the end of 2027. But in the coming years smartphones and PCs/laptops are the segments that would increase the demand for digital writing instruments. Smartphones is expected to grow at a CAGR of 10.9% during the forecast period.

Among various types of *application* in global digital writing instruments market, the digital learning market has the highest market value of over US$ 800 Mn by the end of 2027. Whereas, digital scanning and art & design is expected to register a high growth rate during the forecast period.

The segmentation based on *distribution channel* shows that e-commerce holds the highest market size by 2027, and retail stores is way ahead in terms of growth rate.

*Preview Analysis on Global Digital Writing Instruments Market Segmentation By Product Type- Digital Pens/Pencils, Digital Styli; Device Compatibility - PCs/Laptops, Tablets, Smartphones; Application- Digital Scanning, Digital Learning, Art & Design, Gesture Recognition, Others; Distribution Channel- e-Commerce, Retail Stores*: https://www.futuremarketinsights.com/reports/digital-writing-instruments-market

*Digital Writing Instruments Market: Competitive Landscape*

The report gives the strategic as well as development details of many key players of the global digital writing instruments market. Some of these companies, mentioned in the report are Dell Technologies, Moleskine Srl, Neo Smartpen Inc., FiftyThree, Inc., Luidia, Inc., Hewlett Packard, Lenovo Group, Acer Inc., Adonit, AsusTek Computer Inc., Apple Inc., Microsoft Corporation, Anoto Group AB, Wacom Co., Ltd. etc.

*Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you*: https://www.futuremarketinsights.com/askus/rep-gb-5210

*More from FMI’s Electronics, Semiconductors, and ICT Market Intelligence:*

· *Wearable Fitness Trackers Market *Segmentation By Product Type - Wrist Wear(Bands, Watches), Leg Wear (Shoes, Leg Straps) and Smart Garments; By Application - Pedometer, Heart Rate Monitor, Daily Activity Tracker, Call, Text, & Calendar Alerts, Sleep Tracking and GPS Tracking: https://www.futuremarketinsights.com/reports/wearable-fitness-trackers-market

· *LED Lights Market *Segmentation By Product Type - Lamps and Luminaries; By Sales Channel - Modern Trade, Departmental Stores, Convinience Store, E-Commerce and others; By Application - Residential, Office, Industrial, Shops/Stores and Hospitality:https://www.futuremarketinsights.com/reports/led-lights-market

· *Force Sensor Market *Segmentation By Technology- Capacitive Force Sensor, Piezo-resistive Force Sensor, Piezo-electric Force Sensor, Magneto-elastic Force Sensor, Others (Optical Force Sensor); Application- Monitoring & Control, Testing & Measurement; Vertical- Automotive, Medical & Healthcare, Consumer Electronics, Clothing & Textile, Food & Beverage, Manufacturing, Aerospace & Defence, Oil & Gas, Construction, Agriculture, Others: https://www.futuremarketinsights.com/reports/sensors-market

*About Us*

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

*Browse More **Electronics, Semiconductors, and ICT Market Insights*

*Contact Us*

Mr. Sudip Saha
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Press Office: Press@futuremrketinsights.com
FMI Blog: http://www.fmiblog.com/
Website: www.futuremarketinsights.com Reported by GlobeNewswire 36 minutes ago.

Report: Baking Ingredients Market Size Will Reach US $15.73 Million by 2021

$
0
0
New York, NY, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Zion Research has published a new report titled *“Baking Ingredients Market by Type (Leavening Agents, Fats & Shortenings, Colors & Flavors, Baking Powders & Mixes, Emulsifiers, Starch, Enzymes, Oil and Other Types) for Cakes & Pastries, Bread, Rolls & Pies, Biscuits & Cookies and Other Application: Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”*. According to the report, global demand for baking ingredients market was valued at over USD 11.80 billion in 2015, is expected to reach above USD 15.73 billion in 2021 and is anticipated to grow at a CAGR of slightly above 5.0% between 2016 and 2021. 

Baking is a process which involves radiation and convection technology and the food is baked using prolonged heating. Baking ingredients are the supporting agents in the process of baking. Baking ingredients improve baking and provide high texture, puffiness, and great taste. Baking ingredients ease the process of baking. Some of the frequently used baking ingredients are eggs, yeast, and butter among others.

*Browse through 32 Tables & 26 Figures spread over 110 Pages and in-depth TOC on "Global Baking Ingredients Market Report by Product Type & Applications, 2015-2021”.*

*Request Free Sample copy of Global Baking Ingredients Market Report @ *https://www.zionmarketresearch.com/sample/baking-ingredients-market

Rapidly growing population along with increasing food demand are some of the major drivers of the bread and baked food market. This, in turn, increases the demand for baking ingredients market. The rise in hectic lifestyle with dual income spurs the demand for fast food. This results in the substantial growth of baking ingredients market. Escalating food chain industry and increasing disposable income further, fuels the growth of the market. However, the limited shelf life of the baked products couple with health concern population which hesitates to use refined flour, high fats, and chemicals may impede the demand for these products in the market. Nevertheless, ongoing research and development for introducing gluten-free bread with high nutrition are likely to offer ample opportunities to the baking ingredients market. Moreover, rising demand from the emerging countries owing to increasing attraction for the fast and processed food bid the demand for the bread and baked products in the forecast period.

The baking ingredient market can be segmented based on type and application. On the basis of type, baking ingredients can be classified as leavening agents, fats & shortenings, colors & flavors, baking powders & mixes, emulsifiers, starch, enzymes, and oil. Starch is considered as high potential segment owing to its high demand in baking procedures. Some of the major applications for baking ingredients are cakes & pastries, bread, rolls & pies, biscuits & cookies, and other applications. Bread is the most widely consumed product in the European countries on a daily basis. Though, Biscuits and cookies are also gaining huge demand since past couple of years.

Browse the full "*Baking Ingredients Market by Type (Leavening Agents, Fats & Shortenings, Colors & Flavors, Baking Powders & Mixes, Emulsifiers, Starch, Enzymes, Oil and Other Types) for Cakes & Pastries, Bread, Rolls & Pies, Biscuits & Cookies and other application: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021*" report at https://www.zionmarketresearch.com/report/baking-ingredients-market

North America dominated the baking ingredients market followed by Europe owing to high consumption of bakery products. Moreover, reluctance for cooking on a daily basis leads to high demand for such ready to eat products. The Asia Pacific is considered to be the most prominent market and is likely to gain traction in the forecast period. The factor mainly contributes to the growing bakers is surging demand for bakery products. Latin America is anticipated to experience decent growth over the coming years owing to growing demand for baked products in Brazil. The Middle East and Africa are expected to show sustainable growth owing to improvement in living standards and disposable income.

*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/baking-ingredients-market
 
Some of the key players in the bakery ingredients are Associated British Foods Limited, Cargill, Inc, Royal DSM N.V., Kerry Group plc, Corbian N.V., British Bakels Ltd, Muntons plc, AAK UK, Dawn Foods Ltd, Taura, CSM, Caravan Ingredients, crust ‘n’ crumb food ingredients Pvt Ltd. and Empire Baking Company among others. The presence of various vendors had led intense competition; therefore the companies in this market space must practice constant innovation strategy by focusing on research and product development for maintaining their sales in the market.

*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/113

*This report segments the baking ingredients market as follows:*

*Baking Ingredients Market: Type Segment Analysis*

· Leavening agents
· Fats & shortenings
· Colors & Flavors
· Baking powders & mixes
· Emulsifiers
· Starch
· Enzymes
· Oil
· Other

*Baking Ingredients Market: Applications Segment Analysis*

· Cakes & pastries
· Bread
· Rolls & pies
· Biscuits & cookies
· Other

*Baking Ingredients Market: Regional Segment Analysis*

· North America

· The U.S.

· Europe

· UK
· France
· Germany 

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Food Antioxidants Market:* https://www.zionmarketresearch.com/report/food-antioxidants-market
· *Ready to Drink Tea and Coffee Market:* https://www.zionmarketresearch.com/report/ready-drink-tea-coffee-market
· *Low-Intensity Sweeteners Market:* https://www.zionmarketresearch.com/report/low-intensity-sweeteners-market
· *Cheese Market:* https://www.zionmarketresearch.com/report/cheese-market
· *Beer Market:* https://www.zionmarketresearch.com/report/beer-market

*About Us:*
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research*Follow Us Twitter: *https://twitter.com/zion_research

CONTACT:
Contact Us:

Joel John

244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com Reported by GlobeNewswire 36 minutes ago.

Icy Europe, balmy North Pole: the world upside down

$
0
0
PARIS - Not for the first time in recent years, Europe has descended into a deep freeze while the Arctic experiences record high temperatures, leaving scientists to ponder the role global warming may play in turning winter weather upside down. Reported by Bangkok Post 24 minutes ago.

IMMOFINANZ: Early extension of Executive Board contract with CFO Stefan Schönauer

$
0
0
DGAP-News: IMMOFINANZ AG / Key word(s): Real Estate/Change of Personnel

28.02.2018 / 13:49
The issuer is solely responsible for the content of this announcement.
--------------------
The Supervisory Board of IMMOFINANZ AG today extended the Executive Board contract with Stefan Schönauer ahead of schedule by two further years to 30 April 2021.
 
Stefan Schönauer (38) was appointed to the Executive Board in March 2016 for a period of three years and has since been responsible for accounting, controlling, consolidation, taxes, financing, cash management, IT, procurement and internal audit. He previously held leading positions with IMMOFINANZ since 2008.

The Executive Board contracts for CEO Oliver Schumy and COO Dietmar Reindl run up to February 2020 and April 2021, respectively.

 
*On IMMOFINANZ*
IMMOFINANZ is a commercial real estate group whose activities are focused on the retail and office segments of seven core markets in Europe: Austria, Germany, Czech Republic, Slovakia, Hungary, Romania and Poland. The core business covers the management and development of properties, whereby the STOP SHOP (retail), VIVO! (retail) and myhive (office) brands represent strong focal points that stand for quality and service. The real estate portfolio has a value of approx. EUR 4.2 billion and covers more than 250 properties. IMMOFINANZ is listed on the stock exchanges in Vienna (leading ATX index) and Warsaw. Further information under: http://www.immofinanz.com

*For additional information contact:*
Bettina Schragl
Head of Corporate Communications and Investor Relations
T +43 (0)1 88 090 2290
M +43 (0)699 1685 7290
communications@immofinanz.com
investor@immofinanz.com
 
  --------------------

28.02.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: IMMOFINANZ AG
Wienerbergstraße 11
1100 Wien
Austria
Phone: +43 (0) 1 88090 - 2290
Fax: +43 (0) 1 88090 - 8290
E-mail: investor@immofinanz.com
Internet: http://www.immofinanz.com
ISIN: AT0000809058
WKN: 911064
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Warschau, Wien (Amtlicher Handel / Official Market)
 
End of News DGAP News Service Reported by EQS Group 15 minutes ago.

Wave of New Innovation in Product Launches at the Wearable Technology Show

$
0
0
Wave of New Innovation in Product Launches at the Wearable Technology Show LONDON--(BUSINESS WIRE)--Leading the charge for future emerging connected technology, exhibitors at this year’s Wearable Technology Show will be showcasing some of the hottest and most innovative new products and prototypes of the year. 100 exhibitors from more than 20 countries will be on the show floor to unveil their latest innovations in smart technology, many of which will never have been seen before in Europe. Toshiba, WiTGrip and Thrive Wearables will all be exclusively be launching new Reported by Business Wire 29 minutes ago.

Jumio’s Netverify Wins Award for Best Fraud Protection in the 2018 Cybersecurity Excellence Awards

$
0
0
PALO ALTO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Jumio today announced its Netverify® solution was named the gold winner in the Best Fraud Protection category by the 2018 Cybersecurity Excellence Awards. This is the second time in one month that Netverify has been recognized as a leading ID verification solution. SC Magazine also named Netverify a finalist for its Best Authentication Technology award.The 2018 Cybersecurity Excellence Awards honor individuals and companies that demonstrate excellence, innovation and leadership in information security. Results are determined based on strength of the nomination and a popular vote by members of the Information Security community.

“We are honored to be recognized as the top technology in fraud protection by the 2018 Cybersecurity Excellence Awards,” said Stephen Stuut, CEO of Jumio. “In today’s digital landscape, things we couldn’t have imagined even ten years ago can now be done online with a push of button or through an app. As a result, fraud has increased dramatically across all industries, and it’s now imperative that companies take the extra precaution verifying identities and ultimately safeguarding their customers against fraud.”

Netverify provides real-time identity, ID and document verification using computer vision, biometric facial recognition, artificial intelligence (AI) and identity experts to verify that individuals’ real-world identities match their digital identities and to detect and mitigate online fraud without sacrificing conversion rates. Recently, Jumio surpassed previous records to verify more than 100 million identities using the Netverify solution.

SC Magazine will announce the Best Authentication Technology award winner on April 17 during its gala in San Francisco.

“In an age where threats are ever-evolving, it is reassuring to know that one true constant is the commitment of dedicated information security professionals, as best exemplified by our SC Media Awards finalists,” said Illena Armstrong, VP, editorial, SC Media. “These inspiring innovators have set a high bar for their industry peers, as they continue to protect the world from attacks and vulnerabilities that imperil our security, privacy, and digital infrastructure. The year 2017 brought us WannaCry ransomware infections, the rise of cryptominers, and bugs like Broadpwn and BlueBorne that affected billions of devices. Whatever threats rear their ugly heads in 2018 and beyond, our finalists will be ready to act.”

For more information on Jumio’s award-winning Netverify solution, please visit: https://www.jumio.com/trusted-identity/netverify/

*About Jumio*
When identity matters, trust Jumio. Jumio is the creator of Netverify® which enables businesses to increase customer conversions while providing a seamless customer experience and reducing fraud. By combining the three core pillars of ID Verification, Identity Verification and Document Verification, businesses now have a complete solution that allows them to establish the real-world identity of the consumer.

Leveraging advanced technology like biometric facial recognition, machine learning, artificial intelligence and human review, Jumio helps customers to meet regulatory compliance including KYC, AML and GDPR and tie the digital identity to the physical world. Jumio has verified more than 100 million identities issued by over 200 countries from real time web and mobile transactions. Jumio’s solutions are used by leading companies in the financial services, sharing economy, higher education, cryptocurrency, retail, travel and online gaming sectors.

Based in Palo Alto, Jumio operates globally with offices in the US, Europe, and Asia Pacific and has been the recipient of numerous awards for innovation. For more information, please visit www.jumio.com.

*Media Contacts*
*U.S. Media Contact*
Caitlin Haskins
10Fold Communications
Jumio@10fold.com
415-800-5369 Reported by GlobeNewswire 9 minutes ago.

Utenos Trikotažas Group achieves 13.4% growth in 2017

$
0
0
Utena, Lithuania, 2018-02-28 14:02 CET (GLOBE NEWSWIRE) -- Utenos Trikotažas AB, the largest textile group in Central and Eastern Europe, grew rapidly during 2017, with group sales increasing 13.4% from the previous year to EUR 25.8 million. The Group’s pre-tax profit for 2017 was EUR 435 thousand. The pre-tax profit was negatively impacted by a substantial increase in raw materials prices which was not fully transferred to client prices for products. Wage costs also rose significantly.

Sales of products and services for the company Utenos Trikotažas AB itself increased 15% in 2017 to EUR 22.6 million, of which 82.2% was for export. The Company’s pre-tax profit for the year was EUR 2.25 million, compared with EUR 674 thousand in 2016. Growth of the Company’s pre-tax profit was due to income from subsidiary companies dividends and capital reduction.

“Last year’s sales growth sets a positive tone – sales grew in all business segments. Factors behind that include the groundwork done in export markets and work with new clients as well as expansion of our chain of own-brand stores and the creation of new collections. I’m convinced the Group’s potential to grow rests on the two pillars of our business strategy to be “organically innovative”: first, we focus completely on meeting clients’ needs for top quality manufacturing and product innovation, and second, we take great care to ensure production processes are environmentally friendly and consumer-friendly. Our clients both in Lithuania and abroad really value that,” said Algirdas Šabūnas, the general manager of the Utenos Trikotažas AB group.

Compared to 2016, when the Group had a pre-tax profit of EUR 1.22 million, its smaller pre-tax profit in 2017 was due to sharply increased prices for raw materials as well as complications in the supply of materials which prevented fulfilment of the full potential for client orders. Rapid growth of wages in the Group was partially offset by increased production volumes and orders.

Exports made up 78.7% of the Group’s product sales last year, which is 14.7% more than in 2016. The largest export markets (accounting for 68.1% of all exports) remain Scandinavia and the German-speaking countries Germany, Austria and Switzerland. Exports of goods and services to these regions grew 14.5% during the year to EUR 17.6 million.

Sales in Lithuania also grew significantly and were up 9,0 % in 2017 compared to 2016. Own-brand sales increased 18.0% and made up 13.6% of all Group sales. That was thanks to the renewed UTENOS brand, which is attracting more and more consumer attention, and expansion of the UTENOS chain of branded stores. Late last year 4 new stores were opened – in Mažeikiai, Alytus, Tauragė and Kaunas. In total the Group owns 15 stores throughout Lithuania.

During 2017, the Group invested EUR 0.8 million (twice the 2016 amount) to increase manufacturing capacity and acquire new technological equipment. The same types of investments also dominate plans for 2018. 

“The growing scale of operations lets us continue increasing capacity and production efficiency, thus addressing the challenges of rising labour costs. Operational efficiency is one of the top priorities this year. We hope it will allow us to not only control operating costs, but also successfully fulfil growing client orders,” Algirdas Šabūnas noted.  

The Group ended 2017 with rapid growth: sales of goods and services in the last quarter of the year grew 20.8% versus the same period of 2016. Positive growth dynamics also continue in 2018 – in January the company Utenos Trikotažas AB’s sales exceeded the EUR 3 million mark for the first time in a decade. The last time the company had a bigger monthly result was February 2008, when sales were EUR 3.49 million. 

At the start of last year, the Utenos Trikotažas AB group of companies joined Greenpeace’s “Detox” project to promote fashion without pollution. In joining, the Group committed itself by 2020 to eliminate from its production chain any chemical substances that have an adverse effect on people or the environment. 

The Utenos Trikotažas AB group includes the companies Utenos Trikotažas, Šatrija, Gotija and Mrija (Ukraine). The Group of companies is part of the SBA concern. 

About Utenos Trikotažas AB: 

Utenos Trikotažas AB is the largest and most modern textile group in Central and Eastern Europe and part of the SBA concern. Companies in the Group include Šatrija, Gotija and Mrija (Ukraine). The company Utenos Trikotažas itself owns two retail brands – UTENOS and ABOUT. In 2017, Utenos Trikotažas AB was the first in Lithuania to join Greenpeace’s “Detox” project for fashion without pollution and commit by 2020 to eliminate from its production chain any chemical substances that adversely affect people or the environment.

Utenos Trikotažas AB

Managing Director Algirdas Šabūnas

tel. No. 370 389 51445 Reported by GlobeNewswire 9 minutes ago.

Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018

$
0
0
CORAL GABLES, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the company’s support of the 11^th annual Rare Disease Day on February 28, 2018. Rare Disease Day emphasizes the importance of rare disease research toward the development of diagnostic tools, treatments and cures, as well as improved health and social care for patients and their families.Catalyst continues to support patient organizations that provide disease awareness for Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndromes and anti-body positive MuSK myasthenia gravis. These are rare diseases in which patients are often misdiagnosed with other diseases prior to receiving a definitive diagnosis. Therefore, educating the patient and physicians at medical congresses is an important outreach to the rare disease community to facilitate proper and prompt diagnoses.

“Catalyst is proud to support Rare Disease Day and once again be part of this global movement to raise awareness for rare diseases,” said Patrick J. McEnany, Chairman and CEO of Catalyst. “With the upcoming resubmission of our NDA for Firdapse®, we are one step closer to hopefully being able to provide a treatment for those afflicted by the rare disease Lambert-Eaton Myasthenic Syndrome.”

Rare Disease Day takes place every year on the last day of February (February 28 or February 29 in a leap year) to underscore the nature of rare diseases and the challenges such patients face on a day-to-day basis. It was established in Europe in 2008 by EURORDIS, the organization representing rare disease patients in Europe, and is now observed in more than 80 nations. Rare Disease Day is sponsored in the U.S. by the National Organization for Rare Disorders (NORD)®, the largest and leading independent, nonprofit organization committed to the identification, treatment, and cure of rare diseases and one which Catalyst actively supports.  Additionally, Catalyst supports Global Genes in their efforts to continue to get more patients with rare diseases to take an active role in raising awareness about those diseases.

For more information about Rare Disease Day in the U.S., go to http://www.rarediseaseday.us.  For information about global activities, go to www.rarediseaseday.org. To search for information about rare diseases, visit NORD's website www.rarediseases.org and Global Gene's website https://globalgenes.org/wrdd2018/.

*About Catalyst Pharmaceuticals*

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

*Forward-Looking Statements*

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether the results of the LMS-003 trial, combined with the results of the Company's previous Phase 3 trial, will be acceptable to the FDA as support for an approval of Firdapse for the treatment of LEMS, (ii) whether the results of the abuse liability studies undertaken by Catalyst will be acceptable to the FDA as support for an approval of Firdapse, (iii) whether any NDA submitted for Firdapse will be accepted by the FDA, and the timing of any such submission and acceptance, (iv) whether the receipt of breakthrough therapy designation for Firdapse will expedite the development and review of Firdapse by the FDA or the likelihood that the product will be found to be safe and effective, (v) whether, if an NDA for Firdapse is accepted for filing, such NDA will be given a priority review by the FDA, (vi) whether Firdapse will ever be approved for commercialization, (vii) whether Catalyst will be the first company to receive an approval for amifampridine (3,4-DAP), giving it 5-year marketing exclusivity for its product, and (viii) those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com

Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com Reported by GlobeNewswire 9 minutes ago.

Utenos Trikotazas: Utenos Trikotažas Group achieves 13.4% growth in 2017

$
0
0
Utena, Lithuania, 2018-02-28 14:02 CET (GLOBE NEWSWIRE) -- Utenos Trikotažas AB, the largest textile group in Central and Eastern Europe, grew rapidly during 2017, with group sales increasing 13.4%... Reported by FinanzNachrichten.de 11 minutes ago.

Surgical Tables Market to be worth US$1,014.3 Million by 2022 - Transparency Market Research

$
0
0
Albany, NY, Feb. 28, 2018 (GLOBE NEWSWIRE) -- In accordance to the report by TMR, the international surgical tables market is expected to rise from a market valuation of US$ 837.1 mn in 2017 and is predicted to be worth around US$1,014.3 mn by the year 2022 at a steady growth rate of 3.9% CAGR within the period of forecast that extends from the year 2017 to the year 2022.

*Illness due to Various Lifestyle Factors to Encourage Market Growth*

There are many factors that have been positively impacting the growth of this market. Some of the factors are improvement in the healthcare infrastructure, burgeoning number of accidents, expanding base of geriatric population worldwide, and rising number of surgeries across the globe.

There has been rising incidences of chronic illness as well as various other health-related issues that are necessitating surgeries and these factors are expected to boost the world market for surgical tables. Numerous healthcare centers and hospitals are upgrading to the latest and advanced equipment in a bid to make an offering of effective care to patients and as such it is expected that the said market would receive a boost.

*Request to View Sample of Report - *https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30893

*North America to Lead the Market throughout the Period of Forecast*

The international market for diabetes drugs has been categorized into major geographies of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Based on the segmentation of geography, the region of North America is foreseen to steer the world market for surgical tables towards growth. The said market is estimated to expand from a market valuation of around US$ 246.9 mn in the year 2017 to a valuation of US$ 301.5 mn by the year 2022, thereby registering a healthy growth of 4.1% CAGR from the year 2017 to 2022. The region of Europe is further anticipated to be a major market for surgical tables in the forthcoming years. The said region held around 27.8% of the total market share in the year 2017 owing to the strong backing that it receives from the government for the development and progress of the industry of healthcare together with high number of organizations that are manufacturing medical devices in this region.

*Download PDF Brochure of Report: *https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30893

However, it is the region of Asia Pacific which is foreseen to be a major market driver for the progress of the overall global market for surgical tables in the forthcoming years. Japan held around 9.6% of the total market in the year 2017 and is expected to be a steady contributor towards the market revenue. Asia Pacific except Japan (APEJ) is estimated to rise at a growth rate of around 4.1% CAGR in between the forecast period of 2017 and 2022 and the said market is reach a market evaluation of around US$ 244 mn by the year 2022.

The world market for surgical tables is dominated by already established international market vendors whilst local market participants jostle to make a positive impact on the said industry. Together with the development of advanced and premium quality electro-hydraulic operating tables, electric surgical tables, and operating tables and by offering end-to-end service, these international market players have fortified their foothold in the world market for surgical tables. Whilst on the other hand, numerous local market participants are finding it extremely difficult to meet up with the standard of  the technology, features, and quality that is used in the surgical tables that are being developed by the international market vendors. The global surgical tables market is projected to be extremely fragmented due to the presence of disbanded opportunity that exists across the globe, discovers Transparency Market Research (TMR) in its latest market intelligence report.

*Buy Surgical Tables Market Research Report: *https://www.transparencymarketresearch.com/checkout.php?rep_id=30893&ltype=S

A few of the prominent market players that operate within the surgical tables market are Elekta AB, Stryker Corporation, Span America Medical System Inc., AMTAI Medical Equipment, Inc., Allengers Medical Systems Limited, STERIS, Getinge AB, Skytron Inc., and C-RAD AB.

*About TMR*

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

*Contact*

Mr. Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
*Email*: sales@transparencymarketresearch.com
*Website:* http://www.transparencymarketresearch.com
*Research Blog:* http://theglobalhealthnews.com/ Reported by GlobeNewswire 10 minutes ago.

The Latest: Large part of France on alert for snow, wind

$
0
0
LONDON (AP) — The Latest on the wintry weather conditions across Europe (all times local):12:45 p.m.France's national weather agency, Meteo France, says a large part of the country is on alert for dangerous levels of snow, ice... Reported by New Zealand Herald 13 minutes ago.

Stockholm IT Ventures AB: STOCKHOLM IT VENTURES ANNOUNCES DATE FOR BYTEMINE TOKEN AIR DROP

$
0
0
DGAP-News: Stockholm IT Ventures AB / Key word(s): Miscellaneous

01.03.2018 / 13:00
The issuer is solely responsible for the content of this announcement.
--------------------
*STOCKHOLM, SWEDEN (1 March, 2018)* - Stockholm IT Ventures AB (ISIN SE 0006027546 - Frankfurt Stock Exchange: SVAB), a Swedish technology company specialising in clean and efficient low-cost energy cryptocurrency mining, today announced its airdrop date for its Bytemine token sale on April 20. For updated information about Bytemine follow them on Telegram: @bytemine or https://t.me/bytemine. On Wednesday, March 7, Stockholm IT Ventures will disclose more details about how the free Bytemine tokens are going to be distributed during the upcoming airdrop.
 
"We are pioneering a faster and safer crypto world for miners to thrive and keep the blockchain alive," said Anthony Norman, CEO, Stockholm IT Ventures. "The instability and high cost of the current environment is significantly impacting market growth. Our Bytemine tokens will use clean energy at far less power consumption, reducing barriers to entry making it easier and less expensive for more miners to mine."
 
Stockholm IT Ventures will use the money raised through its ICO to further its commitment to clean-energy mining with a vast majority of the raised funds will be allocated to mining infrastructure. The remaining funds will go towards research and development and administrative needs.
 
*About Stockholm IT Ventures AB*
Stockholm IT Ventures AB is a Swedish public company listed on the Frankfurt Stock Exchange since 2014 under the ticker symbol SVAB. The company focuses on clean and efficient low-cost energy cryptocurrency mining and production, and in blockchain related technology. All mining activities shall use clean and sustainable energy from hydro power stations in Northern Europe, requiring up to 80% less energy compared to ordinary mining for Bitcoin. The Stockholm IT Ventures stock represents a green investment in cryptocurrency technology. For more information, visit www.stockholmit.co. You can also find them on Facebook, Twitter and LinkedIn. You can also purchase their Bytemine tokens at https://www.bytemine.io/.
 
# # #
 
 
*Media Contacts:*
Vibrate Communications for Stockholm IT Ventures
leslie@vibratecommunications.com
tyrone@vibratecommunications.com --------------------

01.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Stockholm IT Ventures AB
Vikdalsgränd 10A
131 27 Nacka Strand
Sweden
Phone: +44 207 148 6262
Internet: www.stockholmit.co
ISIN: SE0006027546
WKN: A116BG
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate Exchange
 
End of News DGAP News Service Reported by EQS Group 1 hour ago.

ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting

$
0
0
*Oral administration of OBE022 shows favorable safety and results in predictable exposure
Non-clinical results of OBE022 for PTL demonstrating fetal safety *

*Geneva, Switzerland and Boston, MA - 01 March 2018* - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced it will make presentations at the 65th Annual Meeting of the Society for Reproductive Investigation (SRI), taking place March 6 - 10, 2018 in San Diego, CA. These presentations will include the following:

· First-in-women (FIW) clinical safety and exposure data following single and multiple oral doses of prostaglandin F2alpha (PGF2alpha) receptor antagonist, OBE022, showing the favorable safety and pharmacokinetic profile of OBE022. In addition, the absence of a clinically relevant effect of food on the absorption of OBE022 will be described (Poster presentation S-038, Saturday March 10^th, 2018).
 
· Non-clinical reproductive safety and exposure data demonstrating the absence of adverse effects of highly selective PGF2alpha antagonist OBE022 on fetal development in rats and rabbits and on pre- and post-natal development in rats (Poster presentation S-037, Saturday March 10^th, 2018).

"We are delighted to be able to update the scientific community on the progress of our preterm labor drug candidate OBE022." commented Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.

"The first administration of a drug candidate to humans always constitutes a major milestone in the development of a drug. Our clinical trial results to date show predictable exposures within the pharmacologically relevant range, including the absence of a food effect that is key for addressing acute PTL.  Importantly, results also support an excellent safety profile, with an absence of adverse effects on the fetus, in contrast to nonspecific prostaglandin synthesis inhibitors that may be used as off label tocolytic therapy, such as indomethacin."

In December of 2017, ObsEva announced the initiation of a Phase 2a study of OBE022 in pregnant women with spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks (PROLONG, NCT03369262).

*About Preterm Labor*

Preterm labor, defined as the birthing process starting prior to 37 weeks of gestation, is a serious condition characterized by uterine contractions, cervical dilation and rupture of the fetal membranes that can lead to preterm birth. According to a study published in the Lancet in 2012, approximately 15 million babies were born before 37 weeks of gestation in 2010, accounting for 11.1% of all live births worldwide. Over 1 million children under the age of five died in 2013 worldwide due to preterm birth complications, and many infants who survive preterm birth are at greater risk for cerebral palsy, delays in development, hearing and vision issues, and often face a lifetime of disability. The rates of preterm births are rising in almost all countries with reliable data for preterm birth, and are associated with an immense financial impact to the global healthcare system.

To date, only treatments with limited efficacy or restrictive safety issues are available to treat preterm labor. In the United States, no drugs are approved for acute treatment of PTL and recommended off-label tocolytic treatments (medications that inhibit labor) include beta-adrenergic receptor agonists, calcium channel blockers, or NSAIDs, which are used for short-term prolongation of pregnancy (up to 48 hours) to allow for the administration of antenatal steroids (e.g. betamethasone). Magnesium sulfate, used for fetal neuroprotection can also be used (up to 48 hours) to inhibit acute preterm labor. Approved tocolytic treatments in Europe include beta-adrenergic agonists, which carry severe maternal cardiovascular risks, and intravenous infusions of atosiban (an oxytocin receptor antagonist).

While prostaglandin inhibitors (NSAIDs) have been shown to be effective for inhibiting preterm labor, use of such drugs is limited, due to the threat of serious and sometimes life-threatening side effects in the fetus. Such side effects may include kidney function impairment, premature constriction of the blood vessel connecting the pulmonary artery and the descending aorta in a developing fetus, and higher risk of thrombosis of the intestinal arteries (a condition called necrotizing enterocolitis).

*About OBE022 and PGF2alpha*

ObsEva is developing OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF2alpha is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that OBE022 markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with prostaglandin inhibitors such as indomethacin.

*About ObsEva*

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

*Cautionary Note Regarding Forward-Looking Statements*

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan,""potential,""will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and related interactions with regulatory bodies, ObsEva's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2016, and other filings ObsEva makes with the SEC from time to time. These documents are available on the Investors page of ObsEva's website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

*Media Contact:
*Liz Bryan
Spectrum Science
lbryan@spectrumscience.com*
*+ 1 202-955-6222 x2526*

*
*Company Contact:
*CEO Office Contact
Shauna Dillon*
*Shauna.Dillon@obseva.ch*
*+41 22-552-1550
*
*
Investor Contact*
*Mario Corso*
*Senior Director, Investor Relations*
*mario.corso@obseva.com
Office +1 857-972-9347*
*Mobile +1 781-366-5726*

*

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/782e8f19-a1ee-4c90-a63e-8b65ecda07d1 Reported by GlobeNewswire 1 hour ago.

Smile Upon Us, Lord, Barbican, London, review: A dreamy, ruminative road-trip

$
0
0
The Vakhtangov State Academic Theatre of Russia return after their sell-out 'Eugene Onegin' in 2015, with this play about the precarious fortunes of poor Jews in Eastern Europe at the start of the twentieth century Reported by Independent 1 hour ago.

Full list of Luton Airport cancellations as cold snap grounds flights to Europe

$
0
0
Full list of Luton Airport cancellations as cold snap grounds flights to Europe Luton Airport has been particularly badly affected by flight cancellations Reported by Bishops Stortford Observer 58 minutes ago.

IDTechEx Show! - Wearable Technology: Growth Opportunities After the Hype

$
0
0
BOSTON, March 1, 2018 /PRNewswire/ -- The IDTechEx Wearable Europe conference and exhibition, to be held on 11-12 April in Berlin Germany, brings together the ecosystem global brands with leading ... Reported by FinanzNachrichten.de 1 hour ago.

Foresight Solar Fund Limited : Notice of AGM

$
0
0
*FORESIGHT SOLAR FUND LIMITED: **NOTICE** OF ANNUAL GENERAL MEETING*

*THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION*

If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.

If you have recently sold or transferred all of your shares in Foresight Solar Fund Limited, please forward this document, together with the accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.

*NOTICE* is hereby given that the Annual General Meeting ("AGM") of the Company will be held at 28 Esplanade, St Helier, Jersey, JE2 3QA on Monday, 11 June 2018 at 9:30am (BST), or at any adjournment thereof, for the purpose of considering and, if thought fit, passing the following resolutions which resolutions 1 to 9 will be proposed as ordinary resolutions and resolutions 10 to 12 will be proposed as special resolutions:

*Ordinary Resolutions*

1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2017 together with the directors' report and auditors' report on those accounts.
 
2. To approve the directors' remuneration report (excluding the directors' remuneration policy, set out on page 49 of the directors' remuneration report), as set out in the Company's annual report and accounts for the financial year ended 31 December 2017.
 
3. To approve the directors' remuneration policy, as set out on page 49 of the directors' remuneration report, which takes effect immediately after the end of annual general meeting.
 
4. To re-appoint KPMG LLP as the Company's auditor to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting at which accounts are laid before the Company.
 
5. To authorise the directors of the Company to determine the auditor's remuneration.
 
6. To approve the Dividend Policy.
 
7. To reappoint Alexander Ohlsson as a director of the Company.
 
8. To reappoint Chris Ambler as a director of the Company.
 
9. To reappoint Peter Dicks as a director of the Company.

*Special Resolutions*

1. *THAT* the Company be and is hereby generally and unconditionally authorised, pursuant to and in accordance with Article 57 of the Companies (Jersey) Law, 1991 (as amended) (the "*Law*") to make market purchases of its own ordinary shares of no par value in the capital of the Company (the "*Ordinary Shares*") on such terms and in such manner as the directors of the Company shall from time to time determine, subject always to the terms of any class rights in the articles of association and provided that:

(a)        the maximum aggregate number of Ordinary Shares hereby authorised to be purchased shall be such number as represents 14.99 per cent of the aggregate number of Ordinary Shares in issue as at 11 June 2018;

(b)        the minimum price which may be paid for an Ordinary Share shall be £0.01;

(c)        the maximum price exclusive of any expenses which may be paid for an Ordinary Share is an amount equal to the higher of (i) 105% of the average of the middle market quotations for an Ordinary Share (as derived from the Daily Official List of the London Stock Exchange plc) for the five business days immediately preceding the date on which such Ordinary Share is contracted to be purchased; and (ii) the higher of the last independent trade and the highest current independent bid on the trading venue on which the purchase is carried out.

(d)        the authority hereby conferred is in addition to all and any authorities in place in respect of market purchases by the Company and shall expire at the conclusion of the Company's next annual general meeting or on the date falling 18 months from the date of the passing of this resolution, whichever is earlier, unless previously revoked, varied or renewed by the Company in general meeting;

(e)        the Company may at any time prior to the expiry of such authority make a contract or contracts to purchase Ordinary Shares under such authority which will or might be completed or executed wholly or partly after the expiration of such authority and may make a purchase of Ordinary Shares in pursuance of any such contract or contracts; and

(f)         the directors of the Company provide a statement of solvency in accordance with the Articles 55 and 57 of the Law.

1. *THAT*, subject to resolution 11 ("*Resolution 10*") above being passed, the Company be and is hereby generally and unconditionally authorised to cancel any shares it repurchases pursuant to Resolution 11 or pursuant to Article 58A(1)(b) of the Law to hold such shares it repurchases pursuant to Resolution 10 as treasury shares to be dealt with in accordance with the provisions of the Law as the directors of the Company see fit.

1. *THAT*, in addition to any existing power and authority granted to the Directors, the Directors of the Company be and are hereby generally empowered to allot Ordinary Shares of no par value carrying the rights, privileges and subject to the restrictions attached to the Ordinary Shares as set out in the articles of association of the Company (the* "Ordinary Shares*") or to grant rights to subscribe for or, to convert securities into Ordinary Shares (''*equity securities*''), including the allotment and grant of rights to subscribe for, or to convert securities into or the sale of, Ordinary Shares held by the Company as treasury shares in each case for cash as if any pre-emption rights in relation to the issue of or sale of shares, as set out in Article 10.2 of the articles of association of the Company and in the Listing Rules made by the Financial Conduct Authority under Part VI of the Financial Services and Markets Act 2000 (as amended), did not apply to any such allotment of or grant of rights to subscribe for or to convert into equity securities or sale, provided that this power:

(a)        shall expire at the conclusion of the Company's next annual general meeting or on the date falling 15 months after the passing of this resolution, whichever is earlier, save that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement as if the power conferred hereby had not expired; and

(b)        shall be limited to the allotment of up to 44,995,209 Ordinary Shares of no par value (representing as at 21 February 2018 approximately 10% per cent. of the issued share capital of the Company).
             

By order of the Board

Alexander Ohlsson - Chairman
*Foresight Solar Fund Limited*

*21 February 2018*

*Registered Office: 28 Esplanade, St Helier, Jersey JE2 3 QA*
*Registered Number: 113721*

Notes:

1. As a member you are entitled to appoint a proxy or proxies to exercise all or any of your rights to attend, speak and vote at the annual general meeting and you should have received a proxy form. . A proxy need not be a member of the Company but must attend the annual general meeting to represent you. You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You can only appoint a proxy using the procedure set out in these notes and the notes to the proxy form. You may not use any electronic address provided either in this notice or any related documents (including the circular and proxy form) to communicate with the Company for any purpose other than those expressly stated.

2. To be valid any proxy form or other instrument appointing a proxy, together with any power of attorney or other authority under which it is signed or a certified copy thereof, must be received by post or (during normal business hours only) by hand at Computershare Investor Services (Jersey) Limited, Queensway House, Hilgrove Street, St. Helier, Jersey, JE1 1ES no later than 48 hours before the time of the meeting or any adjourned meeting.

3. The return of a completed proxy form or other instrument of proxy will not prevent you attending the annual general meeting and voting in person if you wish.

4. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority will be determined by the order in which the names stand in the register of members in respect of the joint holding.

5. Only those shareholders registered in the Company's register of members at 9.30am, on 9 June 2018 (or, if the meeting is adjourned, 48 hours (excluding non-working days) before the time fixed for the adjourned meeting) shall be entitled to attend, speak and vote at the meeting in respect of the number of Ordinary Shares registered in their name at that time. In each case, changes to entries on the register of members of the Company after that time shall be disregarded in determining the rights of any person to attend, speak and vote at the meeting.

6. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution.  If [you either select the "Discretionary" option or if]no voting indication is given, your proxy vote will or abstain from voting at his or her discretion.  Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting.

7. Any person holding five per cent. or more of the total voting rights of the Company who appoints a person other than the chairman of the meeting as his proxy will need to ensure that both he and his proxy complies with their respective disclosure obligations under the UK Disclosure and Transparency Rules.

*Explanation of business *

The Notice of Annual General Meeting contains certain items of business which are of a technical nature and are therefore explained below:

*Resolution 10 - Authority to purchase own Ordinary Shares *

Resolution 11 seeks shareholder authority for the directors of the Company to make market purchases of Ordinary Shares in accordance with the provisions of the Law. In some circumstances companies may find it advantageous to use surplus funds to purchase their own shares in the market. This can lead to increases in net asset value per share on those shares not purchased. The directors of the Company confirm that they will only purchase Ordinary Shares where they believe the effect would be to increase net asset value per share and would be in the best interests of shareholders.

The buy back of the Ordinary Shares referred to in Resolution 11 will allow the Company to cancel such shares or hold them as treasury shares.

*Resolution 11 - Treasury Shares*

Resolution 10 seeks shareholder authority for the directors of the Company to hold shares it repurchases pursuant to special resolution 11 as treasury shares. The Company is able under Jersey law to hold its own shares as treasury shares. If the Company elects to hold the Ordinary Shares it buys back as treasury shares, it will not be treated as a member by virtue of holding such shares. Indeed, it will not be allowed to exercise any voting rights in respect of such shares and the number of treasury shares in issue will not be taken into account when calculating, for the purposes of any resolutions, the total number or any required proportion of shares in issue. The Company cannot make or receive any dividend in respect of treasury shares and cannot exercise or enforce any rights or obligations in respect of such shares.

*Resolution 12 - Authority to allot Shares on a non pre-emptive basis*

Generally, the directors may only allot shares or securities in the Company (or grant rights to subscribe for, or to convert any security into, shares in the Company) if they have been authorised to do so by shareholders and they must first offer such shares or securities to shareholders in proportion to their existing holdings. If passed, in addition to any existing power and authority granted to the Directors, the special resolution will authorise the directors to allot shares in the Company (and to grant rights to subscribe for, or to convert any security into, shares in the Company) up to an additional 44,995,209 Ordinary Shares of no par value as if pre-emption rights did not apply to such allotment immediately following the adoption of this resolution.

*For further information please contact:*

*Foresight Group*
Ricardo Piñeiro*                                                 020 3667 8150*
Tom Moore*                                                       020 3667 8156*

*Stifel Nicolaus Europe Limited                     020 7710 7600*
Mark Bloomfield
Neil Winward
Tunga Chigovanyika Reported by GlobeNewswire 1 hour ago.
Viewing all 65275 articles
Browse latest View live




Latest Images